-- Wyeth profit up on demand for prescription drugs
-- 
-- Tue Jan 30, 2007 8:37am EST
-- http://www.reuters.com/article/2007/01/30/us-wyeth-results-idUSWEN307120070130

 

 NEW YORK  (Reuters) - Wyeth WYE.N reported higher fourth-quarter earnings on Tuesday on increased sales of its prescription medicines, including its Effexor anti-depressant and Prevnar vaccine against childhood infections. 


 Earnings rose to $855 million, or 63 cents per share, from $732 million, or 54 cents a share, a year earlier. Excluding special items, Wyeth said it earned 66 cents per share. Analysts on average expected 71 cents, according to Reuters Estimates. Sales rose 10 percent to $5.22 billion, above the analysts' average forecast of $5.1 billion. Sales of Effexor increased 11 percent to $936 million, while sales of Prevnar jumped 25 percent to $502 million. Wyeth forecast 2007 earnings of $3.40 to $3.50 per share, excluding potential charges resulting from the company's ongoing productivity efforts. Analysts on average expect $3.50, according to Reuters Estimates. The company said it expected net revenue growth in the mid-to-high single digits and gross margins of about 72 percent to 74 percent in 2007. Analysts have forecast revenue of $21.6 billion, up about 6 percent from $20.35 billion reported for 2006. (Additional reporting by  Julie Steenhuysen  in Chicago)